ALK reported FY 2025 revenue of DKK 6,312.00 million (+15%) and EBIT of DKK 1,654.00 million (+53%), with an EBIT margin of 26%. Free cash flow was DKK 1,432.00 million, supported by higher earnings and an upfront payment from a new Chinese partnership with GenSci. For Q4 2025, revenue was DKK 1,733.00 million (+17%) and EBIT was DKK 387.00 million (+88%), with a 22% EBIT margin. By product line in FY 2025, tablet sales were DKK 3,335.00 million (+17%), SCIT/SLIT drops were DKK 2,145.00 million (+5%), and anaphylaxis and other products were DKK 832.00 million (+34%), driven by Jext and neffy. ALK highlighted strong uptake of paediatric launches of ACARIZAX and ITULAZAX, continued roll-out of neffy in Germany and the UK, and progress with partnerships including ARS Pharma, GenSci and Shionogi (Torii). The company said its phase 2 peanut SLIT tablet trial remains on track to report topline results in Q2 2026. ALK’s board recommended FY 2025 dividends of DKK 355.00 million, or DKK 1.60 per share, targeting distribution of about 30% of net profit after tax. For FY 2026, ALK guided for revenue growth of 11–15% in local currencies and an EBIT margin of about 25%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALK-Abelló A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001165795-en) on February 20, 2026, and is solely responsible for the information contained therein.